Madopar Hbs (Benserazide Hydrochloride, Levodopa)

Madopar Hbs is indicated for the treatment of Parkinsonian disorders, where restoration of dopaminergic activity is required.

• Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor.
• Parkinsonian syndrome: alleviates motor dysfunction caused by dopamine deficiency.
• Secondary Parkinsonism: provides symptomatic relief when dopamine pathways are impaired.
• Fluctuating Parkinsonian symptoms: reduces OFF periods and enhances ON time during the day.

• Levodopa crosses the blood‑brain barrier and is decarboxylated to dopamine within central neurons, directly replenishing depleted neurotransmitter levels. Benserazide, a peripheral aromatic L‑amino acid decarboxylase inhibitor, prevents the conversion of levodopa to dopamine outside the brain, thereby increasing the amount of levodopa that reaches the central nervous system and reducing peripheral side effects. The combined formulation thus enhances central dopaminergic stimulation while minimizing systemic adverse reactions.

Levodopa/Benserazide may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

• Nausea: upset stomach often occurring at treatment initiation.
• Vomiting: may accompany nausea, especially with rapid dose escalation.
• Dizziness or light‑headedness: related to orthostatic blood pressure changes.
• Headache: mild to moderate intensity, usually transient.
• Insomnia: difficulty falling or staying asleep.
• Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects

• Dyskinesia: involuntary, erratic movements that can be disabling.
• Hallucinations or psychosis: visual disturbances or altered perception.
• Severe hypotension: marked drop in blood pressure leading to fainting.
• Neuroleptic malignant syndrome: rare but life‑threatening reaction.
• Cardiac arrhythmias: irregular heart rhythms observed in susceptible patients.

When prescribing Madopar Hbs, clinicians should consider several safety measures to optimize benefit and reduce risk.

• Dose titration: start with the lowest effective dose and increase gradually to minimize adverse effects.
• Renal and hepatic function: assess before initiation and adjust in impairment.
• Cardiovascular status: monitor for hypotension, especially in patients with pre‑existing heart disease.
• Pregnancy and lactation: safety not established; use only if potential benefit justifies the risk.
• Concomitant antipsychotics: may diminish therapeutic effect and increase motor complications.
• Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Madopar Hbs can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors: may cause hypertensive crisis when combined.
• Antipsychotics (e.g., haloperidol, risperidone): can block dopaminergic action and reduce effectiveness.
• Iron or calcium supplements: decrease levodopa absorption from the gastrointestinal tract.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: additive blood‑pressure‑lowering effect may require dose adjustment.
• Selective MAO‑B inhibitors (e.g., selegiline, rasagiline): can increase levodopa plasma concentrations and risk of side effects.